Poster Abstract Session:
231. Clinical Study with New Antibiotics and Antifungals
Saturday, October 7, 2017: 12:30 PM-2:00 PM
Room: Poster Hall CD


Presentations:
Meropenem-Vaborbactam Pharmacokinetics in Subjects with Chronic Renal Impairment, Including Hemodialysis
Christopher M. Rubino, Pharm.D.; David C. Griffith, B.A.; Sujata M. Bhavnani, Pharm.D., M.S.; Jeffrey S. Loutit, MBChB; Brooke Lohse, BA; Michael N. Dudley, Pharm.D., FIDSA; Paul G. Ambrose, Pharm.D., FIDSA
First-in-Human Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects
Michael R. Hodges, MBBS, BSc; Eric Ople, BSc; Karen J. Shaw, PhD; Robert Mansbach, PhD; Sjoerd J. Van Marle, MD; Ewoud-Jan Van Hoogdalem, PharmD PhD; Pamela Wedel, BSc; William Kramer, PhD
Posters
  • 1840_IDWPOSTER - upload.pdf (313.7 kB)
  • A Phase 1 Study in Healthy Subjects to Investigate Safety, Pharmacokinetics, and Effect on Intestinal Flora of Multiple Ascending Doses of DS-2969b, A Novel Oral DNA Gyrase B Inhibitor for The Treatment of Clostridium difficile Infection
    Satoshi Inoue, MD, Ph.D; Justin Dennie, PharmD; Yasuo Nagasawa, Ph.D; Roohi Gajee, Ph.D; Nobuhisa Masuda, PhD; Cynthia Zamora, MD; Giorgio Senaldi, MD, Ph.D
    Posters
  • POSTER231_1841.pdf (235.8 kB)
  • Preservation of gut microbiome following ridinilazole versus fidaxomicin treatment of Clostridium difficile infection
    Suparna Mitra, PhD; Caroline Chilton, PhD; Jane Freeman, PhD; Henry Wood, PhD; Phil Quirke, BM, PhD; Morag Taylor, M.Sc; Richard Vickers, PhD; Mark Wilcox, MD
    SYN-004 (ribaxamase) Protects the Diversity of the Gut Microbiome in Patients Receiving Intravenous Ceftriaxone Treatment
    John Kokai-Kun, PhD; Sheila Connelly, PhD; Charles Le, PhD; Kenneth Trout, MS; Joseph Sliman, MD, PhD
    Posters
  • 2017-ID Week-Poster.pdf (829.6 kB)
  • Prevention of Lung Pathology and Mortality in Rabbit Staphylococcus aureus Pneumonia with Cytotoxin-Neutralizing Monoclonal IgGs that Penetrate Epithelial Lining Fluid
    Lukas Stulik, MSc; Harald Rouha, PhD; Delphine Labrousse, PhD; Zehra Visram, PhD; Gabor Nagy, MD, PhD; Delphine Croisier, PhD; Eszter Nagy, MD, PhD
    Intravenous Fosfomycin (ZTI-01) for the Treatment of Complicated Urinary Tract Infections (cUTI) Including Acute Pyelonephritis (AP): Results from a Multi-center, Randomized, Double-Blind Phase 2/3 Study in Hospitalized Adults (ZEUS)
    Keith S. Kaye, MD, MPH; Louis B. Rice, MD, FIDSA; Aaron Dane, MSc; Viktor Stus, MD, PhD; Olexsiy Sagan, MD; Elena Fedosiuk, MD; Anita Das, PhD; David Skarinsky, BS; Paul B Eckburg, MD; Evelyn J Ellis-Grosse, PhD
    Posters
  • Zavante_Poster1845_revCC KS.pdf (105.4 kB)
  • Ceftolozane/Tazobactam Dose Evaluation for Pediatric Subjects with Complicated Intra-Abdominal Infection and Complicated Urinary Tract Infection
    Kajal Larson, PhD; Matthew G. Johnson, MPH; Matthew L. Rizk, PhD; Luzelena Caro, PhD; John S. Bradley, MD, FIDSA, FPIDS, FAAP; Jocelyn Ang, MD; Elizabeth Rhee, MD
    Phase I Study To Evaluate The Pharmacokinetics Of Two Dosing Regimens Of Oral Fosfomycin Tromethamine In Healthy Adult Participants
    Eric Wenzler, PharmD; Susan C. Bleasdale, MD; Monica K. Sikka, MD; Kristen Bunnell, PharmD; Matthew Finnemeyer, MPH; Susan L Rosenkranz, PhD; Larry H. Danziger, Pharm.D., FIDSA; Keith A. Rodvold, Pharm.D., FIDSA
    Population Pharmacokinetic (PPK) Analysis of ZTI-01 (Fosfomycin for Injection) Using Data from Healthy Subjects and Patients with Complicated Urinary Tract Infections (cUTI)
    Michael Trang, Pharm.D.; Evelyn J. Ellis-Grosse, PhD; Paul B. Eckburg, M.D.; David Skarinsky, B.S.; Sujata M. Bhavnani, Pharm.D., M.S.; Christopher M. Rubino, Pharm.D.
    Population Pharmacokinetic Model for Intravenous ASN100 in Healthy Subjects
    Scott A. Van Wart, Ph.D., M.S.; Christopher Stevens, M.D.; Zoltan Magyarics, M.D., Ph.D.; Steven A. Luperchio, Ph.D., CMPP; Paul G. Ambrose, Pharm.D., FIDSA
    A Pharmacometric Comparison of Omadacycline and Tigecycline Epithelial Lining Fluid (ELF) Penetration
    Elizabeth A. Lakota, Pharm.D., M.S.; Keith A. Rodvold, Pharm.D., FIDSA; Sujata M. Bhavnani, Pharm.D., M.S.; Judith N. Steenbergen, PhD; Evan Tzanis, BA; Paul G. Ambrose, Pharm.D., FIDSA; Christopher M. Rubino, Pharm.D.
    Population Pharmacokinetic (PPK) and Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses for Delafloxacin to Support Dose Selection for the Treatment of Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
    Sujata M. Bhavnani, Pharm.D., M.S.; Li Zhang, M.D., Ph.D.; Paul G. Ambrose, Pharm.D., FIDSA; Robert K. Flamm, PhD; Sue K. Cammarata, MD; Christopher M. Rubino, Pharm.D.
    Meropenem-Vaborbactam Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses as Support for Dose Selection in Patients with Normal Renal Function and Varying Degrees of Renal Impairment
    Sujata M. Bhavnani, Pharm.D., M.S.; Michael Trang, Pharm.D.; David C. Griffith, B.A.; Olga Lomovskaya, Ph.D.; Jeffrey P. Hammel, M.S., B.S.; Jeffrey S. Loutit, MBChB; Michael N. Dudley, Pharm.D., FIDSA; Paul G. Ambrose, Pharm.D., FIDSA; Christopher M. Rubino, Pharm.D.
    Improved Outcomes with Plazomicin (PLZ) Compared with Colistin (CST) in Patients with Bloodstream Infections (BSI) Caused by Carbapenem-resistant Enterobacteriaceae (CRE): Results from the CARE Study
    James A. McKinnell, MD; Lynn E. Connolly, MD, PhD; Richard Pushkin, MD; Adrian M. Jubb, MBChB, PhD; Bridget O'Keeffe, PhD; Alisa W. Serio, PhD; Alex Smith, MS; Jonathan Gall, PharmD; Valerie Riddle, MD; Kevin M. Krause, MBA; Jason M. Pogue, PharmD
    Posters
  • IDWeek 2017 Poster 1853.pdf (208.5 kB)
  • Plazomicin Versus Meropenem for Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP): Diagnosis-specific Results From the Phase 3 EPIC Study
    Daniel J. Cloutier, PharmD; Allison S. Komirenko, Pharm.D.; Deborah S. Cebrik, MS, MPH; Tiffany R. Keepers, PhD; Kevin M. Krause, MBA; Lynn E. Connolly, MD, PhD; Florian M.E. Wagenlehner, MD
    Posters
  • IDWeek 2017 Poster 1855.PDF (132.8 kB)
  • Improved Outcomes at Late Follow-up (LFU) with Plazomicin Compared with Meropenem in Patients with Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) in the EPIC Study
    Yoav Golan, MD; Daniel J. Cloutier, PharmD; Allison S. Komirenko, Pharm.D.; Deborah S. Cebrik, MS, MPH; Tiffany R. Keepers, PhD; Kevin M. Krause, MBA; Lynn E. Connolly, MD, PhD; Florian M.E. Wagenlehner, MD
    Posters
  • IDWeek 2017 Poster 1859.PDF (175.1 kB)
  • Phase 1 Study to Assess Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of APX001 and to Investigate the Effect of Food on APX001 Bioavailability
    Michael R. Hodges, MBBS, BSc; Eric Ople, BSc; Karen J. Shaw, PhD; Robert Mansbach, PhD; Sjoerd P. Van Marle, MD; Ewoud-Jan Van Hoogdalem, PharmD PhD; William Kramer, PhD; Pamela Wedel, BSc
    Posters
  • 1860 IDWPOSTER - upload.pdf (286.4 kB)
  • Clinical Outcomes of Serious Infections due to Carbapenem-Resistant Enterobacteriaceae (CRE) in TANGO II, a Phase 3, Randomized, Multi-National, Open-Label Trial of Meropenem-Vaborbactam (M-V) Versus Best Available Therapy (BAT)
    Keith S. Kaye, MD, MPH; Jose Vazquez, MD, FACP, FIDSA; Amy Mathers, MD; George Daikos, MD; Elizabeth Alexander, MD, MSc; Jeffrey S. Loutit, MBChB; Shu Zhang, PhD; Michael N. Dudley, Pharm.D., FIDSA; Oliver Cornely, MD, FACP, FIDSA, FAAM
    RBX2660 is Safe, Superior to Antibiotic-Treated Controls for Preventing Recurrent Clostridium difficile, and May Rehabilitate Patient Microbiomes: Open Label Trial Results
    Robert Orenstein, DO, FIDSA; Erik R. Dubberke, MD, MSPH; Sahil Khanna, MBBS, MS; Gail Hecht, MD; Herbert Dupont, MD; Christine Lee, MD, FRCPC; Ken Blount, PhD; Sharina Carter, PhD
    Phase 3, randomized, double-blind noninferiority (NI) study of ceftazidime-avibactam (CAZ-AVI) versus meropenem (MER) in the treatment of patients with Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP): Analyses of the REPROVE study per US FDA Endpoints
    Antoni Torres, MD, PhD, FERS; Doug Rank, MD; Ludmyla Rekeda, PhD; Xiang Chen, MS; Todd Riccobene, PhD; Ian Critchley, PhD; Hassan Lakkis, PhD; David Melnick, MD; Joseph W. Chow, MD; Dianna Taylor, BSc, PgC; Peter J. Laud, MSc; Angela K. Talley, MD
    Meropenem-Vaborbactam vs. Piperacillin-Tazobactam in TANGO I (a Phase 3 Randomized, Double-blind Trial): Outcomes by Baseline MIC in Adults with Complicated Urinary Tract Infections or Acute Pyelonephritis
    Thomas J. Walsh, MD; Tanaya Bhowmick, MD; Rabih Darouiche, MD; Valerii Zaitsev, MD, PhD; Evangelos Giamarellos-Bourboulis, MD, PhD; Andrew F. Shorr, MD, MPH; Elena Fedosiuk, MD; Thomas M. File Jr., MD, MSc, MACP, FIDSA, FCCP; Jeffrey S. Loutit, MBChB; Olga Lomovskaya, Ph.D.; Michael N. Dudley, Pharm.D., FIDSA; David Perlin, Ph.D.
    Meropenem-Vaborbactam vs. Best AvailableTherapy for Carbapenem-ResistantEnterobacteriaceae Infections in TANGO II: PrimaryOutcomes by Site of Infection
    Richard Wunderink, MD; Evangelos Giamarellos-Bourboulis, MD; Galia Rahav, MD; Amy Mathers, MD; Matteo Bassetti, MD, PhD; Joseph Solomkin, MD, FIDSA; Elizabeth Alexander, MD, MSc; Jeffrey S. Loutit, MBChB; Shu Zhang, PhD; Michael N. Dudley, Pharm.D., FIDSA; Keith S. Kaye, MD, MPH
    Meropenem-Vaborbactam vs. Best Available Therapy for Carbapenem-Resistant Enterobacteriaceae Infections in TANGO II: Outcomes in Immunocompromised Patients
    David L. Paterson, MB BS PhD FRACP FRCPA; Eun J. Kwak, MD; Tanaya Bhowmick, MD; Elizabeth Alexander, MD, MSc; Jeffrey S. Loutit, MBChB; Shu Zhang, PhD; Michael N. Dudley, Pharm.D., FIDSA; Thomas J. Walsh, MD
    Clinical Response of Cefiderocol Compared with Imipenem/Cilastatin in the Treatment of Adults with Complicated Urinary Tract Infections with or without Pyelonephritis or Acute Uncomplicated Pyelonephritis: Results from a Multicenter, Double-blind, Randomized Study (APEKS-cUTI)
    Simon Portsmouth, MD; David Van Veenhuyzen, MBChB, MPharmMed; Roger Echols, MD, FIDSA; Mitsuaki Machida, MS; Juan Camilo Arjona Ferreira, MD; Mari Ariyasu, BA; Tsutae Den Nagata, MD, PhD, FFPM
    Microbiome Profile is Distinct in Patients with Successful Response to Microbiota-Based Drug RBX2660 Relative to Placebo Responders
    Erik R. Dubberke, MD, MSPH; Robert Orenstein, DO, FIDSA; Christine Lee, MD, FRCPC; Sahil Khanna, MBBS, MS; Gail Hecht, MD; Dale N Gerding, MD, FIDSA; Ken Blount, PhD; Bill Shannon, PhD, MBA
    Micafungin versus Posaconazole Prophylaxis in Patients with Acute Leukemia or Myelodysplastic Syndrome: A Randomized, Open-label Study
    David J. Epstein, MD; Susan Seo, MD; Yao-Ting Huang, PhD, MPH; Jae Park, MD; Virginia Kimek, MD; Martin S. Tallman, MD; Mark G. Frattini, MD, PhD; Genovefa Papanicolaou, MD
    Posters
  • poster 1871.pdf (205.8 kB)
  • Immunogenicity of a 2+1 Infant Vaccination Series with 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Followed by Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV): a Randomized Trial Exploring Interchangeability of PCVs
    Abiel Mascareñas De Los Santos, MD; Miguel Angel Rodríguez-Weber, MD; Pedro Sánchez-Márquez, MD; Roberto Carreño-Manjarrez, MD; María Yolanda Cervantes-Apolinar, MD; Javier Ruiz-Guiñazú, MD; Eduardo Ortega-Barria, MD; Dorota Borys, MD
    Assessment of MIC Increases with Meropenem-Vaborbactam and Ceftazidime-Avibactam in TANGO II (a Phase 3 Study of the Treatment of CRE Infections)
    Olga Lomovskaya, Ph.D.; Mariana Castanheira, PhD; Jose Vazquez, MD, FACP, FIDSA; Keith S. Kaye, MD, MPH; Kirk Nelson, BS; Dongxu Sun, PhD; Elizabeth Alexander, MD, MSc; Michael N. Dudley, Pharm.D., FIDSA; Michael Yin, MD
    Analysis of the Microbiological data from the Omadacycline (OMC) Phase 3 Community-Acquired Bacterial Pneumoniae (CABP) trial: The OPTIC study
    Eliana Armstrong, PhD; Evan Tzanis, BA; Amy Manley, BS; Paul McGovern, MD; Anita Das, PhD; Judith N. Steenbergen, PhD
    Treatment of Acute Bacterial Skin and Skin Structure Infection (ABSSSI) with Dalbavancin in Patients with Systemic Inflammatory Response Syndrome (SIRS)
    Michael Nowak, PharmD; Jennifer Nelson, PharmD; Urania Rappo, MD, MS, PharmD; Jie Chen, PhD; Jamie Danelo, PharmD; Pedro L. Gonzalez, MD; Frank LoVecchio, DO, MPH
    Analysis of CAMERA-1 S. aureus Bacteremia Trial Results using the DOOR
    Thomas L. Holland, MD; Joshua S. Davis, MBBS FRACP; Sarah B. Doernberg, MD; Thuy Tien T. Tran, MS; Scott R. Evans, PhD; Sara E. Cosgrove, MD, MS; Helen W. Boucher, MD, FIDSA; G. Ralph Corey, MD; Vance G. Fowler Jr., MD; Henry F. Chambers, MD; Steven Y. C. Tong, MBBS, FRACP
    Meropenem-Vaborbactam: Outcomes in Subjects with Renal Impairment in Phase 3 Studies TANGO I and II
    Amy Mathers, MD; William Hope, BMBS, FRACP, FRCPA, PhD; Keith S. Kaye, MD, MPH; Jeffrey S. Loutit, MBChB; Elizabeth Alexander, MD, MSc; Michael N. Dudley, Pharm.D., FIDSA; Jose Vazquez, MD, FACP, FIDSA
    Phase I Study To Evaluate The Safety And Tolerability Of Two Dosing Regimens Of Oral Fosfomycin Tromethamine In Healthy Adult Participants
    Susan C. Bleasdale, MD; Eric Wenzler, PharmD; Monica K. Sikka, MD; Kristen Bunnell, PharmD; Matthew Finnemeyer, MPH; Susan L Rosenkranz, PhD; Larry H. Danziger, Pharm.D., FIDSA; Keith A. Rodvold, Pharm.D., FIDSA
    Fosfomycin trometamol is noninferior to trimethoprim-sulfamethoxazole for acute uncomplicated cystitis in women
    Ann Stapleton, MD, FIDSA; Pacita Roberts, MS; Marsha Cox, MS; Thomas Hooton, MD, FIDSA
    Pharmacokinetics (PK)/Pharmacodynamics (PD) and Safety of 3 g Ceftolozane/Tazobactam (TOL/TAZ) in Ventilated, Critically-Ill Patients
    Luzelena Caro, PhD; Kajal Larson, PhD; David P. Nicolau, PharmD, FCCP, FIDSA; Jan De Waele, MD PhD; Joseph L. Kuti, PharmD; Elaine Gadzicki, BS; Adedayo Adedoyin, PhD; Zhen Zeng, Ph.D.; Bernardino Mosquera, MD, MPH; Ramanatha Saralaya, MPharm; Elizabeth Rhee, MD
    A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of IV to Oral Omadacycline to Moxifloxacin for the Treatment of Adult Subjects with CABP (The OPTIC Study).
    Roman Stets, MD, PhD; Monica Popescu, MD; Joven Gonong, MD, FPCCP; Ismail Mitha, MD; William Nseir, MD; Andrzej Madej, MD, PhD; Courtney Kirsch, BS; Anita Das, PhD; Lynne Garrity-Ryan, PhD; Judith N. Steenbergen, PhD; Amy Manley, BS; Paul Eckburg, MD; Stephen Villano, MD; Evan Tzanis, BA; Paul McGovern, MD; Evan Loh, MD
    Ceftaroline Fosamil (CPT) versus Vancomycin (VAN) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
    Trang D. Trinh, PharmD, MPH, BCPS, AAHIVP; Evan J. Zasowski, PharmD, MPH, BCPS; Kimberly Claeys, PharmD, BCPS; Abdalhamid M. Lagnf, MPH; Dino Delaportas, MD; Sandy Estrada, Pharm.D., BCPS (AQ-ID); Susan L Davis, PharmD; Kenneth Klinker, PharmD; Vanthida Huang, PharmD; Keith S. Kaye, MD, MPH; Nicole Bonine, PhD, MPH; Patrick Gillard, PharmD, MS; Michael J. Rybak, PharmD, MPH, PhD
    Outcomes of Ceftaroline Fosamil q8h vs q12h Dosing Frequency for High-Burden, Gram-positive Infections
    Sonia Rao, PharmD; Jennifer Hayes, PharmD; Keith S. Kaye, MD, MPH; Jie Chen, PhD; Leonard Johnson, MD

    CME Credits: Maximum of 0.00 hours of AMA PRA Category 1 Credit™


    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.